Effect of PET/CT on management of patients with non - Small cell lung cancer: Results of a prospective study with 5-year survival data

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1007-1015

  Gregory, Deborah L ^a   Hicks, Rodney J ^a   Hogg, Annette ^a   Binns, David S ^a   Shum, Poh Lin ^a   Milner, Alvin ^a   Link, Emma ^a   Ball, David L ^a   Mac Manus, Michael P ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

CT; Diagnosis; Non Small cell lung cancer; PET CT; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT PLANNING; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; BONE AND BONES; CARCINOMA, NON-SMALL-CELL LUNG; CASE MANAGEMENT; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT CARE TEAM; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 84863472505     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.099713     Document Type: Article

References (30)

1. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
2. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
3. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004;5:531-540. (Pubitemid 39194041)
4. Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys. 2008;72:1298-1306.
5. Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G. PET Versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am. 2007;45:639-644. (Pubitemid 47238388)
6. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med. 2009;39:308-340.
7. Schreyögg J,Weller J, Stargardt T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med. 2010;51:1668-1675.
8. Buck AK, Herrmann K, Schreyogg J. PET/CT for staging lung cancer: costly or cost-saving? Eur J Nucl Med Mol Imaging. 2011;38:799-801.
9. Mac Manus MP, Hicks RJ. How can we tell if PET imaging for cancer is cost effective? Lancet Oncol. 2010;11:711-712.
10. Bordoni R. Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist. 2008;13:945-953.
11. Duong CP, Demitriou H, Weih L, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006;33:759-769. (Pubitemid 43979683)
12. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
13. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000;18:106-115. (Pubitemid 30090451)
14. Hicks RJ, Lau E, Alam NZ, Chen RY. Imaging in the diagnosis and treatment of non-small cell lung cancer. Respirology. 2007;12:165-172. (Pubitemid 46239388)
15. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886-895. (Pubitemid 32783077)
16. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287-293. (Pubitemid 32472257)
17. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer. 2010;116:5030-5037.
18. Modi A, Vohra HA, Weeden DF. Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg. 2009;8:467-473.
19. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507. (Pubitemid 36706537)
20. Pauls S, Buck AK, Hohl K, et al. Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin. 2007;46:9-14; quiz N11-12.
21. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005;128:2289-2297. (Pubitemid 41507571)
22. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg. 2004;78:1017-1023, discussion 1017-1023.
23. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011-1019. (Pubitemid 41170866)
24. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48:59-69, quiz N58-59.
25. Billé A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg. 2009;36:440-445.
26. Carnochan FM, Walker WS. Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. Eur J Cardiothorac Surg. 2009;35:781-784, discussion 784-785.
27. 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807-1812.
28. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526-533. (Pubitemid 37310842)
29. Shim SS, Lee KS, Kim BT, Choi JY, Chung MJ, Lee EJ. Focal parenchymal lung lesions showing a potential of false-positive and false-negative interpretations on integrated PET/CT. AJR. 2006;186:639-648. (Pubitemid 46100250)
30. 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients. Cancer. 2007;109:1068-1077.